Prenostics is the key that unlocks precision cancer prevention.

It’s hard to underestimate how important Prenostics is to the practice of oncology; not in the future, but in the here and now.

With a Prenostics Score, health teams can identify who is at risk and what to do next to stop cancer developing.

For some, that could be as simple as a few lifestyle changes.

Others may require a medicine, preventive surgery, or, in the future, a cancer vaccine.

Crucially, Prenostics testing can also track the effectiveness of these interventions, to show whether they have reversed the cancer process.

For those with a strong family history of cancer - or who carry a genetic variant linked to cancer - the fear of diagnosis is never far from our mind.

Although scans and tests provide immediate reassurance, they do not give advanced warning of a precancer so that preventive measures can be taken.

By detecting cancer in its earliest stages of development, Prenostics gives us time to intervene and rewrite the story of our future health.

We’ve known for a long time that cells transitioning to cancer go through a lengthy precancer state which, if detected early enough, can be reversed to normal.

After more than 20 years of research, Prenostics founder Professor Sarah Blagden has discovered a way to detect these precancers.

She identified a unique set of RNA binding proteins that are present in precancers and can be detected using a blood test.

This test generates the Prenostics Score, a tool for physicians and healthcare teams to determine whether a person has a precancer so they can be monitored or receive an intervention.